Protein-Templated Ugi Reactions versus In-Situ Ligation Screening: Two Roads to the Identification of SARS-CoV-2 Main Protease Inhibitors.

MLA

Wamser, Rebekka, et al. “Protein-Templated Ugi Reactions versus In-Situ Ligation Screening: Two Roads to the Identification of SARS-CoV-2 Main Protease Inhibitors.” Chemistry (Weinheim an Der Bergstrasse, Germany), vol. 30, no. 17, Mar. 2024, p. e202303940. EBSCOhost, https://doi.org/10.1002/chem.202303940.

APA

Wamser, R., Zhang, X., Kuropka, B., Arkona, C., & Rademann, J. (2024). Protein-Templated Ugi Reactions versus In-Situ Ligation Screening: Two Roads to the Identification of SARS-CoV-2 Main Protease Inhibitors. Chemistry (Weinheim an Der Bergstrasse, Germany), 30(17), e202303940. https://doi.org/10.1002/chem.202303940

Chicago

Wamser, Rebekka, Xinting Zhang, Benno Kuropka, Christoph Arkona, and Jörg Rademann. 2024. “Protein-Templated Ugi Reactions versus In-Situ Ligation Screening: Two Roads to the Identification of SARS-CoV-2 Main Protease Inhibitors.” Chemistry (Weinheim an Der Bergstrasse, Germany) 30 (17): e202303940. doi:10.1002/chem.202303940.